NITO N2OFF Inc.

Subscribe to $NITO

N2OFF Inc.

Subscribe to $NITO

$NITO

Agricultural Chemicals

Industrials

IPO Year:

Exchange: NASDAQ

Recent Analyst Ratings for N2OFF Inc.

Date	Price Target	Rating	Analyst

See more ratings

N2OFF Inc. Press Releases

Fastest customizable press release news feed in the world

View All

N2OFF: MitoCareX Bio Announces Positive In Vitro Results from Its Mitochondrial Carrier Small Molecule Platform

MITOLINE™ Algorithm Powers Development of First-in-Class Small Molecules Targeting a Mitochondrial Carrier for Inflammatory Metabolic Diseases – A Market Projected to Exceed $120 billion by 2030 Neve Yarak, Israel, Jan. 22, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ:NITO) ("N2OFF" and the "Company"), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, today announced that MitoCareX Bio Ltd. ("MitoCareX Bio"), a specialty biotechnology company developing small‑molecule drugs that target human mitochondrial carriers, its wholly- owned subsidiary, has shown preliminary in vitro data demonstrating inhibition of pro‑inflamm

1/22/26 7:32:00 AM ET

$NITO

Agricultural Chemicals

Industrials

N2OFF: MitoCareX Bio Spotlights Co-Founder's Pioneering Research on Mitochondrial Carriers in Spaceflight Stress Conditions

Neve Yarak, Israel, Jan. 15, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ:NITO) ("N2OFF" and the "Company"), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, today highlighted a newly published peer-reviewed study co-authored by Prof. Ciro Leonardo Pierri, co-founder of MitoCareX Bio Ltd. ("MitoCareX Bio"), N2OFF's wholly-owned subsidiary. The article, appearing in the Journal of Translational Medicine, investigates SLC25A mitochondrial carriers as potential biomarkers and therapeutic targets for dysfunctions induced by spaceflight conditions, including microgravity and cosmic radiation. The study, titled "SLC25A mito

1/15/26 8:32:00 AM ET

$NITO

Agricultural Chemicals

Industrials

N2OFF Advances $340,000 Payment to Gain Better Terms in Flag Solar Energy Initiative, Reflecting Approximately an Additional $1.7 Million in Project Profit Stake

Neve Yarak, Israel, Jan. 05, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ:NITO) ("N2OFF" and the "Company"), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, announced advancement in its European portfolio via its partnership with Solterra Renewable Energy Ltd. ("Solterra"). As announced on December 29, 2025, key milestones in Germany project, which includes solar energy PV and storage assets, have reduced permitting risks, unlocked value through smart capital deployment, and positioned projects for compelling monetization optionality. Key Investor Highlights Reduction in permitting and regulatory risk across core Eu

1/5/26 9:20:00 AM ET

$NITO

Agricultural Chemicals

Industrials

N2OFF Accelerates European Renewable Energy Momentum with Major De-Risking Milestones and Approximately $1.69 Million Value Unlock in Germany and Italy

Neve Yarak, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ:NITO) ("N2OFF" and the "Company"), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) business model, today announced advancement in its European portfolio via its partnership with Solterra Renewable Energy Ltd. ("Solterra"). Key milestones in Germany and Italy have reduced permitting risks, unlocked value through smart capital deployment, and positioned projects for compelling monetization optionality. Key Investor Highlights Permitting Risk Reduced: Strong progress with zero objections in Germany's public consultation and formal planning submissions in Italy, delivering enhance

12/29/25 8:22:00 AM ET

$NITO

Agricultural Chemicals

Industrials

N2OFF: MitoCareX Identifies Hit Compounds and Targets Preclinical Candidate Nomination

Neve Yarak, Israel, Nov. 18, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ:NITO) ("N2OFF"), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) business model, following the completion of its acquisition of MitoCareX Bio Ltd., today shared an update from the Chief Executive Officer of MitoCareX, Dr. Alon Silberman, including a shareholder letter that outlines the company's strategic direction, near-term milestones, and development plans within the rapidly expanding precision oncology market. Dear Shareholders, It is with great enthusiasm that we share with you the progress and vision of MitoCareX Bio Ltd., a pioneering biotechnology company powered by MI

11/18/25 9:12:00 AM ET

$NITO

Agricultural Chemicals

Industrials

N2OFF Completed Merger with Cancer Drug Discovery Company Targeting Tough-to-Treat Pancreatic and Lung Cancers

Neve Yarak, Israel, Oct. 30, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ:NITO) ("N2OFF" and the "Company"), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) business model, recently announced the closing of the merger with MitoCareX Bio Ltd. ("MitoCareX"), a biotech company focused on drug discovery targeting cancer therapeutics, with a range of other potential diseases and disorders, through targeting the mitochondrial SLC25 protein family. MitoCareX is focusing on the development of novel therapies for hard-to-treat cancers by targeting proteins belonging to the mitochondrial SLC25 protein family. Central to this effort is MITOLINE™, MitoCareX's pr

10/30/25 9:25:00 AM ET

$NITO

$SPRC

Agricultural Chemicals

Industrials

Biotechnology: Pharmaceutical Preparations

Health Care

SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

TEL AVIV, Israel, Oct. 23, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the closing of the sale to N2OFF, Inc. (NASDAQ:NITO) ("N2OFF") of SciSparc's majority owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"). MitoCareX is focusing on the development of novel therapies for hard-to-treat cancers by targeting proteins belonging to the mitochondrial SLC25 protein family. Central to this effort is MITOLINE™, MitoCareX's proprietary algorithm that enables reliable 3D comparative modeling of mitochon

10/23/25 4:03:00 PM ET

$NITO

$SPRC

Agricultural Chemicals

Industrials

Biotechnology: Pharmaceutical Preparations

Health Care

N2OFF Announces Closing of Merger with Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

Neve Yarak, Israel, Oct. 23, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ:NITO) ("N2OFF" and the "Company"), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) business model, announced today the closing of the merger with MitoCareX Bio Ltd. ("MitoCareX"), a biotech company focused on drug discovery targeting cancer therapeutics, with a range of other potential diseases and disorders, through targeting the mitochondrial SLC25 protein family. MitoCareX is focusing on the development of novel therapies for hard-to-treat cancers by targeting proteins belonging to the mitochondrial SLC25 protein family. Central to this effort is MITOLINE™, MitoCareX's propr

10/23/25 8:25:00 AM ET

$NITO

$SPRC

Agricultural Chemicals

Industrials

Biotechnology: Pharmaceutical Preparations

Health Care

N2OFF Regains Compliance with Nasdaq Minimum Bid Price Requirement

Neve Yarak, Israel, Oct. 08, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ:NITO) ("N2OFF" and the "Company"), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) business model, announced that it has received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq"), informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). The Company had previously announced on March 28, 2025, that it was notified by Nasdaq that it was not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), as the clos

10/8/25 9:00:00 AM ET

$NITO

Agricultural Chemicals

Industrials

SciSparc: N2OFF Shareholders Approve Merger with SciSparc's Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

TEL AVIV, Israel, Sept. 29, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that on September 25, 2025, the stockholders of N2OFF, Inc. (NASDAQ: NITO) ("N2OFF") voted on and approved, among other things, the proposed acquisition of SciSparc's majority owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"). This important milestone, achieved at N2OFF's special meeting of stockholders held on September 25, 2025, clears a key path for the completion of the Acquisition, which would result in MitoCareX beco

9/29/25 4:03:00 PM ET

$NITO

$SPRC

Agricultural Chemicals

Industrials

Biotechnology: Pharmaceutical Preparations

Health Care

N2OFF Inc.

Recent Analyst Ratings for N2OFF Inc.

N2OFF Inc.

Recent Analyst Ratings for N2OFF Inc.

N2OFF Inc. SEC Filings

N2OFF Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

N2OFF Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities

N2OFF Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Submission of Matters to a Vote of Security Holders

SEC Form 10-Q filed by N2OFF Inc.

Amendment: N2OFF Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

SEC Form DEF 14A filed by N2OFF Inc.

SEC Form SCHEDULE 13G filed by N2OFF Inc.

SEC Form PRE 14A filed by N2OFF Inc.

N2OFF Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

N2OFF Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

N2OFF Inc. Press Releases

N2OFF: MitoCareX Bio Announces Positive In Vitro Results from Its Mitochondrial Carrier Small Molecule Platform

N2OFF: MitoCareX Bio Spotlights Co-Founder's Pioneering Research on Mitochondrial Carriers in Spaceflight Stress Conditions

N2OFF Advances $340,000 Payment to Gain Better Terms in Flag Solar Energy Initiative, Reflecting Approximately an Additional $1.7 Million in Project Profit Stake

N2OFF Accelerates European Renewable Energy Momentum with Major De-Risking Milestones and Approximately $1.69 Million Value Unlock in Germany and Italy

N2OFF: MitoCareX Identifies Hit Compounds and Targets Preclinical Candidate Nomination

N2OFF Completed Merger with Cancer Drug Discovery Company Targeting Tough-to-Treat Pancreatic and Lung Cancers

SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

N2OFF Announces Closing of Merger with Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

N2OFF Regains Compliance with Nasdaq Minimum Bid Price Requirement

SciSparc: N2OFF Shareholders Approve Merger with SciSparc's Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

N2OFF Inc. Insider Purchases

Director Rosenbloom Ronen bought 50,000 units of Restricted Shares of Common Stock, increasing direct ownership by 345% to 64,500 units (SEC Form 4)

N2OFF Inc. Insider Trading

New insider Silberman Alon claimed ownership of 454,127 shares (SEC Form 3)

New insider Scisparc Ltd. claimed ownership of 490,751 shares (SEC Form 3)

Chief Financial Officer Barda Lital was granted 300,000 units of Restricted Shares of Common Stock (SEC Form 4)

Chief Executive Officer Palach David was granted 600,000 units of Restricted Shares of Common Stock (SEC Form 4)

Director Sidi Liat was granted 50,000 units of Restricted Shares of Common Stock (SEC Form 4)

Director Arbib Eliahou was granted 50,000 units of Restricted Shares of Common Stock, increasing direct ownership by 345% to 64,500 units (SEC Form 4)

Director Berenstein Israel Yakov was granted 50,000 units of Restricted Shares of Common Stock, increasing direct ownership by 345% to 64,500 units (SEC Form 4)

Director Kalifi Udi Ovadia was granted 50,000 units of Restricted Shares of Common Stock, increasing direct ownership by 271% to 68,457 units (SEC Form 4)

Director Itzhaik Asaf was granted 50,000 units of Restricted Shares of Common Stock (SEC Form 4)

Director Weiss Amitay was granted 350,000 units of Restricted Shares of Common Stock, increasing direct ownership by 350% to 450,000 units (SEC Form 4)

N2OFF Inc. Financials

N2OFF Announces Strategic Initiatives Intended to Maximize Shareholder Value